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Fetal grafting in a human diseased brain was thought to be less immunogenic than other solid organ transplants,
hence the minor impact on the efficacy of the transplant. How much prophylactic immune protection is required
for neural allotransplantation is also debated. High-sensitive anti-HLA antibody screening in this field has never
been reported. Sixteen patients with Huntington’s disease underwent human fetal striatal transplantation in the
frame of an open-label observational trial, which is being carried out at Florence University. All patients had
both brain hemispheres grafted in two separate robotic–stereotactic procedures. The trial started in February
2006 with the first graft to the first patient (R1). R16 was given his second graft on March 2011. All patients
received triple immunosuppressive treatment. Pre- and posttransplant sera were analyzed for the presence of
anti-HLA antibodies using the multiplexed microsphere-based suspension array Luminex xMAP technology.
Median follow-up was 38.5 months (range 13–85). Six patients developed anti-HLA antibodies, which turned
out to be donor specific. Alloimmunization occurred in a time window of 0–49 months after the first neurosur-
gical procedure. The immunogenic determinants were non-self-epitopes from mismatched HLA antigens. These
determinants were both public epitopes shared by two or more HLA molecules and private epitopes unique to
individual HLA molecules. One patient had non-donor-specific anti-HLA antibodies in her pretransplant serum
sample, possibly due to previous sensitization events. Although the clinical significance of donor-specific anti-
bodies is far from being established, particularly in the setting of neuronal transplantation, these findings under-
line the need of careful pre- and posttransplant immunogenetic evaluation of patients with intracerebral grafts.
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INTRODUCTION
Huntington’s disease (HD) is an incurable autosomal
dominant genetic disorder caused by increased cytosine–
adenine–guanine (CAG; codes for glutamine) repeats on the
huntingtin gene (36). The presence of mutant huntingtin
ultimately results in neuronal degeneration (32). Onset is
typically in middle age when motor, cognitive, and psy-
chiatric impairments start and progressively lead to death
within 15–20 years. The medium spiny projection neurons
of the caudate and putamen are the first to be lost, preced-
ing degeneration in other areas. Fetal-derived cell trans-
plantation is an experimental therapy aimed at replacing
degenerated neurons, thereby preventing or retarding disease
progression (12,38). The Italian experience with intracere-
bral transplantation of human striatal primordia has been
reported (11,13,14). This procedure was thought to be less
immunogenic than other solid organ transplants, hence of
minor impact on the efficacy of the transplant. How much
prophylactic immune protection is required for neural
allotransplantation is also a matter of debate. Attention to
histocompatibility has been high since the beginning in
our framework, with preliminary data made available (28).
Whereas several studies have demonstrated that the pres-
ence of donor-specific antibodies (DSA) and/or non-DSA
significantly correlates with lower graft survival after solid
organ transplantation (18,39), the occurrence of anti-human
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leukocyte antigen (HLA) antibodies in sera of transplanted
HD patients has not found obvious correlations with
clinical outcome (13,20,21). The detection of DSA in
an allograft recipient should always be considered as
indicative of an immune system priming toward major
histocompatibility complex (MHC) antigens. Principally
for logistic reasons, HLA matching is not performed at
the time of transplantation. Therefore, the presence of
possibly unacceptable antigens and the application of
more or less stringent virtual cross-match rules are unfea-
sible. At the very least, recipients who presented with
such antibodies should be considered to be at a higher
risk level than negative subjects (15) and have immuno-
suppression modulated accordingly (13). Since the time
between grafting and allogeneic sensitization was shown
to be unpredictable, irrespective of immunosuppressive sta-
tus, the appropriateness of long-term treatment has been
cast into doubt (20). More data are needed to assess the
significance of circulating antibodies in this setting. This
study is auxiliary to the main clinical trial in investigat-
ing as systematically as possible posttransplant humoral
response to MHC antigens by more sensitive flow-based
bead assays in the largest cohort of HD patients receiv-
ing neurotransplantation.
MATERIALS AND METHODS
Recipients and Donors
This study was authorized by the Italian National Health
Institute, National Transplantation Center (upon approval
by Health Ministry, Consiglio Superiore di Sanità, Sessione
XLV, Sezione II, 7/21 and 9/22/2005, and acceptance by
the National Bioethics Committee). All patients gave writ-
ten informed consent prior to being enrolled in the study.
Patients followed a standard set of neurological, neuro-
psychological, neuropsychiatric, and imaging assessments
at defined intervals over a minimum of 1 year before and
up to 7 years after transplantation.
The source of the grafts was tissue dissected from both
whole ganglionic eminences of electively aborted fetuses at
a gestational age of 9–12 weeks. One randomly assigned
fetus for each transplant was needed. The use of human
fetal tissue was conducted according to the guidelines of
the Italian National Health Institute and approved by the
National Bioethics Committee and the Committee for
Investigation in Humans of the University of Florence. In
particular, items to be fulfilled included (i) distinct separa-
tion between the research team and the institution carry-
ing out the pregnancy interruption, (ii) lack of benefits for
the transplantation and obstetric teams, and (iii) request of
donor’s consent after pregnancy interruption. Fetal mate-
rial was minced into fragments to obtain a tissue suspen-
sion suitable for transplantation. A detailed description
has previously been provided (11,14).
Cytofluorimetric Characterization
One small aliquot of dissociated cells from striatal
fragments was analyzed for the expression of surface
antigens and viability using flow cytometry. Cells were
incubated with fluorescein isothiocyanate (FITC), mouse
anti-human cluster of differentiation 45 (CD45), and
FITC mouse anti-human HLA-DR, -DP, -DQ (Miltenyi
Biotec, Bergisch Gladbach, Germany). Ten microliters of
each antibody have been used in each test tube follow-
ing the manufacturer’s instructions. A volume of 10 µl of
7-aminoactinomycin D (BD Bioscience Pharmingen, San
Diego, CA, USA) was added to identify dead cells. Non-
specific fluorescence and morphologic parameters were
determined by incubation of the same cell aliquot with
isotype-matched mouse monoclonal antibodies (BD Bio-
science Pharmingen). Flow cytometric acquisition was per-
formed by collecting 104 events on a FACSCalibur (BD
Bioscience, San Jose CA, USA). Data were analyzed on
dot-plot biparametric diagrams using Cell Quest software
(BD Bioscience).
Surgical Procedure
The transplantation procedure was described previously
(11). Briefly, transplantation involved bilateral robotic–
stereotactic (Schaerer Mayfield NeuroMate, Lyon, France)
caudate–putaminal grafting of striatal fetal tissue in two
sessions, 2–7 months apart. Fifty microliters of tissue sus-
pension was injected along each track within 4–6 h from
tissue harvesting.
Immunosuppression Protocol
The immunosuppression protocol originally included
oral administration of methylprednisolone (40 mg/daily for
3 days after surgery then tapered and discontinued within
2 weeks), azathioprine (3 mg/kg/daily for 12 months), and
cyclosporine (CSA; 5 mg/kg/daily for 12 months) starting
from 1 day before the first procedure. These drugs were
from Hexal, Holzkirchen, Germany. On the basis of the
clinical course of R1 (14), we modified the immunosup-
pression protocol by continuing CSA administration to sen-
sitized patients sine die. CSA serum levels were checked
weekly for the first 2 months and bimonthly thereafter.
Immunogenetic Assessment and Monitoring
Histocompatibility testing included recipients’ and donors’
low-resolution HLA-A, -B, -DRB1, -DQB1 typing, and anti-
HLA antibody detection and identification by complement-
dependent cytotoxicity (CDC) and Luminex™ techniques
before transplantation. Each patient was scheduled to be
screened for the presence of anti-HLA antibodies at each
clinical follow-up evaluation, excluding the first week
postsurgery visit. Extra scheduled laboratory checks were
performed at every emerging event.
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HLA Typing
HLA-A, -B, -DRB1, and -DQB1 typing was performed
by using DNA extracted (QIAamp DNA Mini Kit;
Qiagen, Hilden, Germany) from peripheral blood mono-
nuclear cells (patients) or wasted tissues (donor fetuses),
amplified by polymerase chain reaction, and then hybrid-
ized with sequence-specific oligonucleotide probes by using
a commercially available (INNO-LiPA, Innogenetics, Gent,
Belgium) line probe assay based on the reverse hybridization
principle. An Auto-LiPA instrument (Innogenetics, Ghent,
Belgium) was used to perform the hybridization. Results
were analyzed by using the LiRAS (Innogenetics) interpre-
tation software. The resolution of typing was from low to
intermediate level. Throughout the text and tables, the sero-
logical equivalents were used, for example, A1 per A*01.
Search for Anti-HLA I and II Antibodies
Pretransplant sera were investigated for the presence of
complement-binding anti-HLA class I alloantibodies by CDC
test. Panel-reactive lymphocytotoxic antibodies (PRA) were
determined in a standard microlymphocytotoxic assay using
a cell tray containing a panel of 56 cells (Lymphoscreen
HLA-ABC 60; Bio-Rad, Hercules CA, USA). The test was
performed according to the manufacturer’s instructions.
Pre- and posttransplant sera were analyzed for the pres-
ence of anti-HLA class I and class II IgG alloantibodies
using the multiplexed microsphere-based suspension array
Luminex xMAP technology. LABScreen® Mixed and
LabScreen® Single Antigen (One Lambda, Canoga Park,
CA, USA) color-coded microbeads coated with purified
HLA antigens were used for detection and identification,
respectively. Any HLA antibodies present in the sera were
bound to the LABScreen® surface antigens coating the micro-
bead and were subsequently labeled with R-phycoerythrin
(PE)-conjugated goat anti-human IgG. The microbead fluo-
rescent emission of R-PE was then detected and quantified
by the LABScan™ 100 flow analyzer (One Lambda). Data
analysis was performed with HLA Fusion™ software (One
Lambda) according to the manufacturer’s guidelines. Posi-
tive posttransplant sera were also reassessed by CDC test.
RESULTS
The present study includes 16 HD patients (11 males,
5 females) who received transplantation at the University
of Florence. Selected relevant features of the patients and
their 32 donors are displayed in Tables 1 and 2. Patients’
disease burden (26) ranged from 214 to 761 (mean 430.6;
standard deviation 148.4). Mean gestational age of the
donor fetuses was 75.0 ± 6.6 days. Viability of cell prepa-
rations was 84.3 ± 6.9% and contained 1.5 ± 1.5% CD45+
cells and 1.6 ± 1.3 class II HLA+ cells.
Prospective immunogenetic monitoring spanned 13 to
85 months (median 38.5 months). Only the first patient
(R1) was positive at CDC test. As already reported, R1’s
posttransplant study showed 18% and 9% PRA for class I
and class II HLA antigens, respectively (14,28). Once her
two pregnancies were excluded as the immunizing event,
identification pointed to DSA (Table 1). Five patients (R2,
R4, R7, R8, R12) developed DSA as detected by Luminex
xMAP technology (Table 1). Apart from R1, we were able
to determine the time window of occurrence of alloimmuni-
zation in the other patients’ sera collected at follow-up.
Anti-HLA antibodies appeared in between 0 and 49 months
after the first surgery. Pretransplant serum from R14
resulted positive, which may be due either to the presence
of “natural” antibodies (25) or to alloimmunization that
occurred with the pregnancies (Table 1). On the other
hand, nine patients were still negative at their last serolog-
ical check 13–63 months from the first graft (Table 2).
According to the Kaplan–Meier analysis, half of the
patients will develop DSA by 40 months (Fig. 1).
R1 has generated DSA anti-B58(17) and anti-DR7.
Besides DSA mounted against DR16, R2 showed anti-
bodies anti-DR4 and anti-DR1. R4 has produced DSA
versus DQ7(3). HLA-DQB1 typing has in fact showed
that the DR4 fetus was DQ7 as the other DR11 fetus.
This remained valid for R7, who has developed anti-DQ7
DSA. Anti-B57(17) and anti-DR52 DSA were present in
R8. As expected, HLA-DRB3 typing demonstrated that
8D2 fetus was indeed DR52. R12 has produced anti-
DR7 DSA, together with anti-B8.
Overall, these results indicate that an important propor-
tion of transplanted HD patients display in their sera
alloantibodies specific for the mismatched HLA class I and
class II antigens from the graft. The immunogenic deter-
minants were the aminoacidic substitutions in the poly-
morphic positions of the HLA molecules, the epitopes.
These determinants were both public epitopes shared by
two or more HLA molecules (cross-reactive group, CREG)
(30) and, to a lesser extent, private epitopes unique to
individual HLA molecules.
DISCUSSION
The brain was once thought to be an immunologically
privileged site, owing to absent antigen-presenting cells
(APCs) and lymphatic drainage and to the blood–brain
barrier (10). Indeed, the central nervous system (CNS)
possesses a diverse range of APCs that facilitate immune
surveillance. Moreover, the cerebrospinal fluid serves as the
equivalent of lymph in the CNS (29). Reactive microglia
expressing HLA-DR molecules have long been detected in
many neurological conditions including HD (23), and acti-
vated T-cells have been shown to traffic through the CNS to
exert immune surveillance (17). Furthermore, class I MHC
is present in specific subsets of CNS neurons, and a function
for class I MHC in neuronal signaling and activity-dependent
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synaptic plasticity in the brain both during development
and in the adult has been hypothesized (33).
The use of allogeneic neural precursor cells as a
replacement therapy in neurodegenerative disorders has
been proposed (27). Nevertheless, both constitutive MHC
gene expression and possible induction of an inflamma-
tory response following implantation need to be taken into
consideration since inflammatory cytokines can upregulate
MHC expression on transplanted cells (19,22,37), thereby
rendering them more susceptible to alloimmunization and
eventually to chronic graft rejection even in the presence of
immunosuppressive drugs (2). Neurotransplantation clini-
cal trials in HD have definitely documented that the CNS
exhibits immunological competence through the processing
and the identification of allogeneic stimuli provided by
the graft, which in turn elicit antibody production (13,20,
21). The reaction takes place during immunosuppressive
treatment and is reminiscent of the humoral response gener-
ally detected before renal graft failure in chronic rejection.
In our series, a serum taken from R1 19 months after
her first implant, and 7 months after immunosuppression
was discontinued, eventually showed positive results for
both anti-HLA class I and class II antigens. Identification
pointed to anti-B17 and anti-DR7 DSA. A serum from R4
14 months after receiving his first graft, and 2 months after
CSA discontinuation, also showed DSA. According to a
prudence principle, a CSA regimen has been reintroduced
for R1 and R4. Since then, immunosuppression was rein-
stated whenever DSA were detected (R2, R7, R8, R12).
The balance of long-term immunosuppression has seen a
reduction of antimetabolites, which block the proliferation
of lymphocyte precursors, whereas administration of inhibi-
tors of cytokine production has been maintained (1).
This study assessed anti-HLA sensitization by new and
more sensitive solid phase assays, in particular flow-based
bead assays such as the Luminex™ system (7). Therefore,
we were able to precisely identify both immunogenicity
(induction of specific antibodies) and antigenicity (reactiv-
ity with antibodies) of epitopes found on the grafted mate-
rial (8,24). R1 developed DSA versus B58(17) and DR7.
Interestingly, 1D1 and 1D2 had four HLA-A antigens
all belonging to 1CREG, two of whom, A29 and A30,
belong to the broad specificity A19. 1D1 and 1D2 also
presented with one 5CREG antigen each, B58 and B18.
The sensitization toward A32 and B5 may have been
triggered by public epitopes shared by those antigens.
Since R1 was not studied before grafting, a role for immu-
nogenic epitopes exposed with pregnancies cannot be
ruled out. Besides DSA raised against DR16, which was
present in 2D1, R2 showed antibodies anti-DR4 and
anti-DR1. Since 2D2 had DR10, it may be argued that
the shared epitope (16) between DR antigens of these
two donors might have had a role. R4 developed
DSA versus DQ7(3). It should not go unnoticed that, as
the two donors of R1 share the class II antigen DR7,
those of R4 are both DQ7. Genomic typing has in fact
shown that the DR4 fetus was DQ7 as the other DR11
fetus. This also held true for R7, who produced anti-DQ7
DSA. Noteworthy, 7D1 and 7D2 presented with one 1CREG
antigen each, A3 and A26(10). Sensitization toward
A66(10) may have been triggered by public epitopes
shared by those antigens. In addition, 7D2 had one 7CREG
antigen, B41, whose immunogenicity might be accounted
for the presence of a number of anti-7CREG antibodies
(but not anti-B41 itself) in R7 posttransplantation sera.
It is tempting to speculate that both the immunogenic
and the antigenic burden brought by the second graft could
be faced by memory T-cells able to mediate rapid recall
responses after restimulation with antigen. In fact, we docu-
mented that our cell preparations from the isolated fetal
striatal tissue contained a small fraction of CD45+ and/or
class II HLA+ cells.
Although the appearance of anti-HLA antibodies may
now be considered the rule, rather than the exception, its
clinical significance remains unclear (13,20,21). Krystkowiak
and coworkers (21) described a HD patient showing both
clinical and neuroimaging signs of graft rejection 14 months
after transplantation, which were readily reversed by reintro-
ducing immunosuppression. Capetian and coworkers (4)
had the chance to study autoptic material from a HD
patient deceased 6 months after grafting. They identified
grafted neuronal progenitors within cuffs of CD4+ and
CD8+ T-cells around vessels in the so-called Virchow–
Robin space. The influence of the transplantation proce-
dure, that is, the tissue trauma inflicted by the implantation,
the preparation of cell suspension, and the site of implan-
tation, together with possible immunomodulatory effects
of neural stem cells on microglial activation have also been
considered (3). Other authors observed neither important
inflammatory/immune reaction nor cuffing in the grafted
Figure 1. Kaplan–Meier estimate of the cumulative risk of
alloimmunization.
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area at postmortem examination 18 months from surgery
(9). However, the same group when inspecting the brain
of HD patients deceased a decade after transplantation
found CD8+, CD4+, and HLA-DR+ cells, indicating an
ongoing immune response that may have contributed to
the disease-like degeneration of the graft observed in
those long-term HD patients (6). Unfortunately, none of
them have been searched for the presence of DSA. Con-
versely, we could not perform histological analysis of the
brains of the three deceased patients of our series, who
died due to common causes in HD (34) and who did not
have clinical graft-related events or any imaging sign of
aberrant tissue development. As a matter of fact, we have
never observed either neovascularization or signs of
neighboring tissue infiltration. This holds true also for
those patients who showed remodeling of the basal gan-
glia anatomy as a result of graft development (13,14).
Despite all the above, sensitization to HLA alloantigens
has appeared so far in 6 of 16 transplanted HD patients
without overt signs of rejection. Whether seroconversion
will ensue also in the other HD patients of our series
remains to be seen at follow-up. Also, the extent to which
alloimmunization will be a significant complication of
neurotransplantation is still unknown, but will possibly be
clarified in the ongoing trial. It should also be recognized
that the biological significance of very low antibody
levels, or of antibodies that do not bind complement, is
yet not completely understood (31,35). Thus, the use of
increasingly sensitive methods such as flow-based bead
assays for antibody detection may represent a crucial
caveat when trying to make correlations with clini-
cal outcome.
The direction, if any, of the clinical outcome associ-
ated with the presence of an immune response toward
intracerebral fetal striatal grafts is undetermined at pres-
ent. Interestingly, Krebs and coworkers (20) reported on
the improvement of chorea in those grafted HD patients
who developed anti-HLA antibodies. However, neuro-
imaging had a relationship neither with immune reaction
nor with clinical response. Thus, both biological and clin-
ical significance of these findings remains uncertain, and
further observations are warranted on more patients for a
longer time. We showed previously that in four patients of
the present series (R1, R4, R6, and R8), the clinical
response measured in terms of motor and behavioral indi-
ces was associated with an outgrowth of striatal-like imag-
ing features occurring in the left side in R1, in the right
side in R4, and bilaterally in R6 and R8 (13). Immunoge-
netics was considered unlikely to explain the pattern of
graft growth in those different recipients. Two of them
were positive for the presence of DSA. Noticeably, DSA
have in the meanwhile appeared in the serum of R8, that
is, one of the two patients who were negative at the time
of our previous report (13). R6, who also presented with
those peculiar neuroimaging features, up to now, is indeed
negative. However, she is presently under immunosup-
pression, and it was decided not to discontinue it. Even
though more cases, according to a predefined statistical
power analysis, and longer posttransplant monitoring are
needed to eventually suggest that anti-HLA antibodies
could affect transplant function, our findings indicate that
donor–recipient histocompatibility issues deserve careful
consideration for the bad, the good, and the unknown (5).
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